This post was originally published on this site People with sarcoidosis have a higher degree of physical inactivity compared with healthy individuals, a pilot study led by researchers from the King’s College London shows. Physical activity monitors, such as the accelerometer device ActivPal, can provide a unique perspective on the impact of sarcoidosis on patients’…
This post was originally published on this site Tecentriq in combination with Abraxane, a chemotherapy, continues to prolong overall survival in adults with triple-negative breast cancer (TNBC) who test positive for the PD-L1 factor, a new interim analysis from a Phase 3 trial shows. These findings were detailed in an oral session, “IMpassion130: updated overall survival (OS)…
This post was originally published on this site Genentech, a subsidiary of Roche, has launched a new substudy to learn more about the progression of early-onset familial Alzheimer’s disease, as part of its ongoing Alzheimer’s Prevention Initiative (API) trial evaluating crenezumab for preventing or delaying this genetic form of the disease. This substudy will examine the…
This post was originally published on this site The Alzheimer’s Association has chosen the summer solstice, June 21, to shed light on Alzheimer’s disease and to raise awareness about the mind-altering, life-changing condition through a fundraising event called The Longest Day. The second purpose is to raise funds for research to benefit the 53 million…
This post was originally published on this site To help find innovative ways to detect, treat, and prevent ovarian cancer, the Ovarian Cancer Research Alliance and the American Cancer Society plan to jointly invest $8 million in four multidisciplinary research projects, yet to be announced. The four-year initiative, which also seeks to prevent disease relapse…
This post was originally published on this site Adding Darzalex (daratumumab) to the standard first-line treatment of Revlimid (lenalidomide) plus dexamethasone improves treatment and survival outcomes in multiple myeloma patients who are not eligible for an autologous stem cell transplant, a Phase 3 clinical trial shows. Findings from the MAIA trial (NCT02252172) were published in The New…
This post was originally published on this site The European Commision has converted the conditional approval of Servier‘s Pixuvri (pixantrone) into a standard marketing authorization, allowing the treatment’s use by people with aggressive non-Hodgkin’s B-cell lymphoma whose cancer has returned or has not responded to other chemotherapies, the company announced. Pixuvri is a chemotherapeutic agent that…
This post was originally published on this site Combining bemcentinib with Keytruda (pembrolizumab) has shown efficacy and led to longer survival than previous second-line treatments in patients with advanced non-small cell lung cancer (NSCLC), according to updated results of a Phase 2 trial. The research, “A phase II study of bemcentinib (BGB324), a first-in-class highly…
This post was originally published on this site Severe diarrhea is a side effect experienced by more than one-third of women with HER2-positive early-stage breast cancer receiving secondary treatment with Nerlynx (neratinib). But preventive treatment with loperamide (brand name Imodium A-D, among others) and other anti-diarrheal medications reduces the severity and duration of this complication,…
This post was originally published on this site A Phase 2a trial testing Oryzon’s investigational therapy vafidemstat for Alzheimer’s disease has enrolled its first patient in the U.S. The trial (NCT03867253), called ETHERAL-US, is an extension of the European trial (2017-004893-32), currently ongoing at 17 sites in the U.K., France, and Spain. Oryzon is planning…
